Worth Venture Partners’s DiaMedica Therapeutics DMAC Stock Holding History

Worth Venture Partners’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-42,887	Closed	-$182K	–	109
2020 Q3	$182K	Buy	+42,887	New	+$227K	0.15%	95
2020 Q2	–	Sell	-105,842	Closed	-$296K	–	127
2020 Q1	$296K	Sell	105,842 -16,314	-13%	-$67.4K	0.18%	63
2019 Q4	$593K	Sell	122,156 -19,645	-14%	-$61.1K	0.29%	44
2019 Q3	$294K	Buy	141,801 +9,287	+7%	+$30K	0.17%	60
2019 Q2	$657K	Buy	132,514 +12,651	+11%	+$43.7K	0.36%	41
2019 Q1	$544K	Sell	119,863 -10,000	-8%	-$36.1K	0.3%	44
2018 Q4	$377K	Buy	+129,863	New	+$408K	0.29%	51

Other funds holding DMAC

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MHP

Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return

GPCM

Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Worth Venture Partners's DMAC Position: Q4 2020 in Review

Worth Venture Partners sold out of DiaMedica Therapeutics (DMAC) in Q4 2020, closing a stake of 42,887 shares — an estimated $182K sold.

Worth Venture Partners first reported a position in DMAC in Q4 2018 and held it in 7 quarters. The position peaked at $657K in Q2 2019. 36 funds tracked by Wall St. Rank hold DMAC as of Q4 2020.

Worth Venture Partners reported no remaining DiaMedica Therapeutics position as of Q4 2020 after selling out during the quarter.
Worth Venture Partners sold 42,887 DiaMedica Therapeutics shares in Q4 2020, an estimated $182K.
Worth Venture Partners first reported a position in DiaMedica Therapeutics in Q4 2018 and held it in 7 quarters.
Worth Venture Partners's DiaMedica Therapeutics position peaked at $657K in Q2 2019.
36 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q4 2020.

Based on Worth Venture Partners's 13F filing for Q4 2020, filed 17 Feb 2021.